Trillium Therapeutics Inc (TRIL)

[NY1972]

PD-L1 was detected with the highest frequency in thymic carcinoma (63%), followed by lymphomas (42%), head and neck squamous carcinoma (35%), anal carcinoma (31%), non-small cell lung cancer (30%), thyroid carcinoma (29%), bladder carcinoma (22%), cervical carcinoma (20%), melanoma (19%), and esophageal and GE junction carcinoma (15%). Significant differences between genomically defined cancer subtypes were observed (e.g. 4-fold more frequent PD-L1 expression in MSI-H colorectal and endometrial carcinomas vs. MSS counterparts).

http://abstracts.asco.org/176/AbstView_176_170639.html